-29 were female, and 4 were male. The age range was 12 to 70 years, with a mean age of 37.
Introduction
Systemic lupus erythematosus (SLE) is the prototypic systemic autoimmune disease with variable multisystem involvement. Hematologic abnormalities involving multiple cell lineages are common in SLE. Lymphopenia was present in 75% among a large cohort of SLE patients and occurred more frequently than any other criterion used to classify the disease. 1 Anemia is estimated to occur in about 50% of patients. 2 While anemia of chronic disease and iron deficiency are quite common, autoantibody-or complement-mediated autoimmune hemolytic anemia are occasionally encountered. 3 Autoimmune thrombocytopenia can result in severe thrombocytopenia and bleeding diatheses. Another less common cause of thrombocytopenia is thrombotic microangiopathy, a complication that also leads to a Coombs' negative hemolytic anemia owing to microvascular thrombosis. 4 Finally, neutrophil abnormalities may include neutropenia, excessive NETosis, and the appearance in the peripheral blood of a population of low density granulocytes. 5 Whereas cytopenias in SLE are typically secondary to peripheral destruction, acquired bone marrow failure is a rarely reported mechanism of cytopenias in SLE. Myelodysplastic syndrome, 6 aplastic anemia (AA), 7 paroxysmal nocturnal hemoglobinuria (PNH), 8 autoimmune myelofibrosis (AIMF), 9 pure red cell aplasia 10 and hemophagocytosis 11 have all been described in SLE. Therefore, it is essential to determine the cause of the hematologic abnormality in the patient with SLE as treatments may vary dependent upon the underlying pathology.
In this review, we present two cases of AIMF in SLE as well as two cases of AA, one with features of PNH. We conducted a review of the current literature with the goal of more clearly characterizing cases of AIMF, AA and PNH associated with SLE. Specifically, we collected information regarding SLE serologies, hematologic manifestations, bone marrow findings, treatment, and outcomes. We discuss current theories on the pathophysiology of AIMF, AA and PNH in SLE and the challenge inherent in differentiating them from primary hematological disorders. We suggest diagnostic and therapeutic strategies for these disorders in SLE based on lessons learned from the present and previous cases.
Case Reports

Autoimmune myelofibrosis
A 69-year-old female with SLE consisting of arthritis presented with lethargy and both a malar and discoid rash on exam. She was not receiving any therapy at the time of admission. Leukocyte count was 2.3 × 10 9 /l with lymphopenia (0.4 × 10 9 /l), hemoglobin was 8.6 g/dl, and platelets were 19 × 10 9 /l. Reticulocyte index was 0.3. Anti-nuclear antibody titer was 1:1280; anti-double stranded DNA antibody was 234 IU/ml (normal < 30 IU/ml); anti-Smith was negative. C3 and C4 were 17.4 mg/dL (88-252 mg/dL) and 4.6 mg/dL (13-75 mg/dL), respectively. Direct Coombs' test was negative. Computed tomography did not reveal splenomegaly. A bone marrow biopsy revealed reticulin fibrosis with plasmacytosis ( Figure  1) . A diagnosis of AIMF was made. High dose steroids were given without improvement in thrombocytopenia. Intravenous immunoglobulin (IVIG) was given for 5 days with gradual improvement. However, 3 days after completion of IVIG, the hemoglobin dropped to 6.6 g/dl. Initially negative 18 days prior, the direct Coombs' test was positive for immunoglobulin G, and elution yielded anti-A and anti-B antibodies. Immune-mediated hemolysis secondary to IVIG was diagnosed, and her anemia stabilized with transfusions. One month later, all counts were normal.
A 55-year-old African American female with SLE previously consisting of arthritis and nephritis on mycophenolate mofetil (MMF) presented with severe lethargy but no significant findings on exam. Leukocyte count was 3.3 × 10 9 /l with lymphopenia (900/uL), hemoglobin was 7.3 g/dl, and platelets were 23 × 10 9 /l. Reticulocyte index was 0.7, and there was no evidence of hemolytic anemia. Anti-nuclear antibody titer was 1:2560; anti-double stranded DNA antibody was 213 IU/ml. C3 and C4 were 49 mg/dL and 14.1 mg/dL, respectively. Computed tomography did not reveal splenomegaly. MMF was discontinued, and high dose steroids were administered. However, there was no improvement in pancytopenia. A bone marrow biopsy revealed reticulin fibrosis with plasmacytosis. IVIG was given without improvement. Labs were also notable for undetectable fibrinogen, with elevated D-dimer and international normalized ratio, suggestive of disseminated intravascular coagulation. The patient expired shortly thereafter. neutropenia (820/uL), hemoglobin was 6.3 g/dl, and platelets were 4 × 10 9 /l. Reticulocyte index was 0.2, and there was no evidence of hemolytic anemia. Anti-nuclear antibody titer was 1:640; anti-double stranded DNA antibody was 74 IU/ml, while anti-Smith was negative. C3 and C4 were 68.1 mg/dL and 20.1 mg/dL, respectively. Computed tomography did not reveal splenomegaly. A bone marrow biopsy revealed marked hypocellularity, but no cellular atypia. A diagnosis of aplastic anemia was made. High dose steroids and intravenous cyclophosphamide were given; however, repeat bone marrow biopsy revealed persistent hypocellularity. She was then given antithymocyte globulin for 5 days, and cyclosporine was started. She had only a partial response (leukocyte count unchanged; hemoglobin (8.7 g/dL) and thrombocytopenia (34 × 10 9 /l) improved but still transfusion dependent), and therefore therapy with eltrombopag was initiated.
Aplastic anemia and PNH
A 70-year-old Indian female presented with gingival bleeding and a petechial rash. Leukocyte count was 2.4 × 10 9 /l with lymphopenia (800/uL) and neutropenia (660/uL); hemoglobin was 8.9 g/dl, and platelets were 2 × 10 9 /l. Reticulocyte index was 0.5. Lactate dehydrogenase was 226 (135-225 U/L), haptoglobin was undetectable, and direct Coombs' test was positive for immunoglobulin G with elution revealing a panagglutinin. Anti-nuclear antibody titer was 1:1280; anti-double stranded DNA antibody was 162 IU/ml, while anti-Smith was negative. Complement levels were normal. The dilute Russell's viper venom time prolongation was felt to represent a lupus anticoagulant. Computed tomography did not reveal splenomegaly. An initial bone marrow biopsy revealed polyclonal B lymphocytosis and plasmacytosis, and a second biopsy 12 weeks later also revealed hypocellularity ( Figure  2 ). She was given high dose steroids, IVIG, and intravenous rituximab without improvement. Peripheral blood flow cytometry revealed a significant paroxysmal nocturnal hemoglobinuria phenotype of red blood cells (CD59 deficient), granulocytes (CD16, CD24 deficient and aerolysin positive), and monocytes (CD14 deficient). Therapy with antithymocyte globulin and cyclosporine was initiated. The patient remained transfusiondependent, and a peripheral smear now revealed 3-4 schistocytes per high power field. Plasma exchange, which was initiated for concern of cyclosporine-induced thrombotic thrombocytopenic purpura, resulted in improvement in hemolysis. Peripheral blood flow cytometry revealed an increase in the PNH clone in granulocytes and monocytes, which was much greater than the clone of PNH red blood cells. This in combination with elevated serum LDH (607 U/L) and undetectable haptoglobin suggested ongoing hemolysis, and eculizumab treatment was initiated.
Review of Published Cases
Method
Using PubMed, a Boolean search of the literature was performed by crossing the keywords "systemic lupus erythematosus," AND ["bone marrow fibrosis" or "bone marrow failure" or "myelofibrosis" or "aplastic anemia" or "paroxysmal nocturnal hemoglobinuria"]. We also examined additional references from the articles we obtained from this method. The articles were written between 1969 and 2016. Only papers written in English were reviewed.
Discussion
Pathophysiology of bone marrow failure in SLE
The attribution of bone marrow failure to SLE can be particularly difficult. There have been several theories posited regarding how SLE may contribute to AIMF, AA and PNH. First, myelofibrosis has been described as a clonal proliferation of myeloid stem cells accompanied by replacement of the bone marrow stroma with fibrous tissue. In SLE, circulating immune complexes and autoantibodies may act on megakaryocyte Fc-receptors and release growth factors, such as platelet-derived growth factor and transforming growth factor-β, which are both known to induce collagen production. 12, 13 Complement system activation is part of SLE pathogenesis, 14 and may contribute to bone marrow failure. Activation of the alternative complement pathway has been described in SLE. 15 In a case series of myelofibrosis, activation of the alternative pathway of the complement system was reported in 4 patients, 2 of which had a positive ANA. 16 It is interesting to note that in all AIMF cases reviewed here where serology was reported, hypocomplementemia was universal (the case reported in Lau et al 1969 was before the assessment of complement as a measure of SLE disease activity was routinely done in clinical practice). 17 Despite these observations, no specific antibodies or biomarkers in SLE have confirmed pathologic associations with myelofibrosis.
The association of SLE with AA in terms of invoking an autoimmune mechanism is perhaps less controversial than with AIMF. There have been 6 instances where an inhibitor in SLE serum has been identified: in 3 cases, a complement-dependent IgG antibody; in 1 case, a non-complement-dependent IgG antibody; and in 2 other cases an inhibitor was not identified. [18] [19] [20] [21] [22] These complement or non-complement-dependent antibodies inhibit in vitro bone marrow colony formation from granulocyte-macrophage progenitor cells 18, 19 and blast-forming units-erythroid. 19 Autoantibodies against various proteins, such as kinectin, moesin and diazepam-binding inhibitor-related protein have been described and may have a subsidiary role in the pathophysiology of AA. 23 In addition, apoptotic bodies have been discovered in the bone marrow of SLE patients, findings not present in normal bone marrow. 24 Whereas their significance is uncertain, delayed clearance of apoptotic debris leads to prolonged exposure of autoantigens and predisposes to antibody production. Other studies have failed to detect inhibiting antibodies, which suggests that other mechanisms are involved in the pathogenesis of AA. For example, T cell dysregulation may play a role. Cytokines such as IFNγ and TNFα are elevated in SLE and contribute to pathogenesis. 14 
Secretion of IFNγ and TNFα by T cells suppresses proliferation of early and late
hematopoietic progenitor and stem cells. These cytokines induce expression of Fas receptor on CD34 + progenitor cells, and triggering by Fas ligand initiates apoptosis. 7 A unique form of AA, pure red cell aplasia, has also been described in SLE and is characterized by severe normocytic anemia, reticulocytopenia, and an absence of erythroblasts from an otherwise normal marrow. 25 Similar to AA, a serum inhibitor is implicated in the majority of cases. 26, 27 Antibodies against erythropoietin have been identified. 28 Also analogous to AA, suppression of erythropoiesis seems to be mediated by T lymphocytes in a subset of patients. 27, 29 Anderson et al.
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The basic defect in PNH is a somatic mutation in the PIG-A gene that causes loss of the glycosylphosphatidylinositol (GPI) anchor proteins on blood cells. Loss of GPI proteins, namely the delay accelerating factor (DAF or CD55) and the membrane inhibitor of reactive lysis (MIRL or CD59) proteins, results in increased susceptibility to complement-mediated lysis of erythrocytes, leukocytes, and platelets. A deficiency of CD55 and CD59 on peripheral blood cells has been described in SLE patients without a diagnosis of PNH. 30, 31 In SLE, excessive complement activation causes damage to tissue and autologous cells. 14 These could include bone marrow progenitor cells in the setting of CD55 and CD59 deficiency. It is interesting to note that PNH clones have been found in a large percentage of cases of bone marrow failure; in one large series, a clone was present in about 1/3 of 200 AA cases and 20% of approximately 100 myelodysplasia cases. 32 Furthermore, small clones are present in a large proportion of AA patients, and these clones may expand over time to cause clinically significant hemolysis. 33 It is not unreasonable to speculate that the development of PNH clones in a SLE patient may leave them more susceptible to complement-mediated hemolysis, given that SLE patients often have an activated complement system. Also of note, there is existing evidence that autoimmunity may play a role in PNH, as it does in AA. Previous reports have documented abnormalities in the T-cell repertoire in PNH, and recent evidence has shown the pathogenic role of a specific subset of cytotoxic T-cells. 34 Furthermore, evidence suggests that cells harboring a PIG-A mutation may escape this cytotoxic attack. 35 Therefore, the cytotoxic T-cells may allow a growth advantage to PNH clones in this disease. 33
Diagnostic and therapeutic strategies
This review of AIMF, AA and PNH in the setting of SLE, as well as our own cases in which there was diagnostic confusion in regards to whether SLE was contributing to bone marrow failure, allows us to suggest some diagnostic and therapeutic strategies.
Autoimmune myelofibrosis may be more prevalent in SLE than the literature suggests. The first case of AIMF was described in 1984, and in 1993, there were 8 reported cases of AIMF in SLE. Herein, we reviewed 33 cases, demonstrating that the number of reported cases has risen significantly. 36, 37 Furthermore, we reviewed 27 cases of AA, and in these cases the absence of reticulin fibrosis was not often specified. Therefore, the distinction between AIMF and AA in SLE is not always clear, and AIMF may thus be underreported. This observation emphasizes that one must have a heightened suspicion for AIMF in cases of pancytopenia in SLE, especially since pathologists do not routinely stain for reticulin. It is notable that some authors suggest that autoimmune disease such as SLE should be sought when myelofibrosis occurs in the absence of the JAK2 mutation. 38 This mutation has been found in up to 50% of those with primary myelofibrosis. 39 Bone marrow fibrosis in SLE usually responds to corticosteroids, as opposed to primary myelofibrosis. In non-responders to corticosteroids in AIMF, IVIG has been used in 4 previous cases, with 2 responding favorably. 9, 38, 40, 41 Our case was unique in that AIMF did not respond to corticosteroids, yet IVIG was ultimately successful, despite the uncommon complication of immune-mediated hemolysis. Of note, plasma exchange has not been efficacious in AIMF. 9 In contrast, plasma exchange has uniformly resulted in complete recovery from AA attributed to SLE when an inhibitor has been found in serum. [18] [19] [20] [21] In these cases, SLE disease-phase serum suppressed the in vitro growth of progenitor cells from bone marrow of normal donors, confirming the presence of a serum inhibitor. The fact that an inhibitor was found in 50% of the 12 AA cases in which it was sought, coupled with complete recovery with plasma exchange, illustrates that plasma exchange is an effective therapeutic option in AA and SLE.
It is imperative to include PNH in the differential when pancytopenia presents in the setting of SLE, especially since aplastic anemia and PNH have close clinical and pathophysiological connections. The risk of developing PNH is approximately 15-25% in patients with acquired aplastic anemia. 42 At the initial diagnosis of aplastic anemia, more than 20% of patients display a small or moderate GPI-deficient clonal population in the bone marrow. 43 Therefore, testing for a significant PNH clone with flow cytometry, as done in the cases reviewed here, is important especially in non-responders to treatment for AA. This is highlighted in the case described here in which AA therapy was unsuccessful, and the patient was transfusion-dependent in the setting of ongoing hemolysis. In this case, eculizumab was initiated. Eculizumab binds to the complement component C5 and prevents its cleavage to C5a and C5b, which is required for formation of the membrane attack complex (MAC). 44 Red blood cells (RBCs) are normally protected from MAC formation by the GPI-linked protein CD59 on their surface; PNH RBCs lacking CD59 are susceptible to MAC formation. Eculizumab interferes with this step and thus reduces intravascular hemolysis. The efficacy of eculizumab was shown in two trials in PNH, the randomized controlled TRIUMPH study and the prospective SHEPHERD study. 45, 46 Both studies demonstrated decreased transfusion requirements, improved laboratory indicators of ongoing hemolysis and better quality of life in the transfusion arm. These studies illustrate that the identification of a PNH clone is essential in the setting of AA, as well as when faced with pancytopenia in the setting of SLE, as eculizumab is an effective therapy. However, supportive care or steroids may be helpful as an initial therapy of PNH in the setting of SLE, as shown by the 3 previous cases reported here.
Conclusion
The diagnosis and treatment of AIMF, AA and PNH is challenging. Furthermore, when these are the first manifestation of SLE, the diagnosis of SLE and the attribution of bone marrow failure to SLE are even more challenging. Table 1 Autoimmune Myelofibrosis: Demographic, Hematologic, and Immunologic Data Table 2 Aplastic Anemia: Demographic, Hematologic, and Immunologic Data Table 3 Paroxysmal Nocturnal Hemoglobinuria: Demographic, Hematologic and Immunologic Data 
